MUMBAI, India & JERSEY CITY, N.J. Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, ...

India’s 2026 M&A wave highlights strategic acquisitions across pharma, banking and retail, reshaping how companies expand and ...

PSL Limited on April 30 sold six-tenth of a percent stake in Sun Pharma Advanced Research Company, a clinical-stage ...

Lower valuation, balance sheet strength and asset risks shape the deal; analysts draw contrasts with earlier buys by Indian ...

The Indian pharma tycoon has made 17 acquisitions before this, but this is the first time he's borrowing money for a buyout.

Days after Sun Pharmaceutical Industries announced its $ 11.75 billion deal to acquire United States-based healthcare company ...

All cash acquisition boosts global footprint and biosimilars push while analysts flag integration risks and debt concerns ...

The acquisition will position India's largest drug company among the top 10 global players in biosimilars and expand its ...

Sun Pharmaceutical Industries' acquisition of US-based Organon & Co at USD 11.75 billion enterprise valuation is both a ...

Sun Pharma will pay $14.00 per share cash for Organon, targeting early-2027 close subject to regulatory and shareholder ...

And yet, the man who authored this audacious move—executive chairman Dilip Shanghvi, now 70—said what he always says when the ...

Sun Pharma's $11.75 billion buyout of Organon signifies a strategic shift from focusing on the US generics market to seeking ...